110 results
Page 3 of 6
8-K
EX-99.1
371o2ye9iluv8b
22 Oct 20
Regulation FD Disclosure
1:14pm
8-K
EX-99.1
ux4g2i8g86l
30 Sep 20
Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies
8:05am
8-K
EX-1.1
pn9840j ddlv
26 Aug 20
Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock
4:10pm
424B5
h0jxl8tf
26 Aug 20
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
ek7o0xoo
25 Aug 20
Other Events
7:00am
8-K
EX-99.2
tgo8chyg7o6j1
25 Aug 20
Other Events
7:00am
8-K
EX-99.1
xtw48c1dxg0yh39
19 Jun 20
Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome
8:06am
8-K
EX-99.1
ojjn40xz k7v3qhp
17 Jun 20
Regulation FD Disclosure
1:11pm
8-K
EX-99.2
foj bckmp4j
7 May 20
Ovid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
8:10am
8-K
EX-99.1
3azt vwak
30 Mar 20
Ovid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome
8:05am
8-K
EX-99.1
cdfjebb b2ug5w
13 Mar 20
Regulation FD Disclosure
9:06am
8-K
EX-99.1
jb3tomflu2h7c3fy
11 Mar 20
Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020
8:05am
8-K
EX-99.1
tw1 9n2vh6tlb
2 Mar 20
Regulation FD Disclosure
3:48pm
8-K
EX-99.1
fudpaits iyk5x
7 Jan 20
Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform
8:05am
424B5
zvbgyege2j2yhft ilu9
12 Nov 19
Prospectus supplement for primary offering
8:02am
8-K
EX-99.1
h2mwybic kx8k
8 Nov 19
Ovid Therapeutics Reports Third Quarter 2019 Financial Results and Recent Progress
8:05am